Study of the anthrax vaccine after exposure
Part of Infections clinical trials.
This study looks at people who received the CYFENDUS vaccine after being exposed to anthrax during a mass exposure event in the United States. It aims to see if the vaccine is safe and works well to prevent anthrax disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You received at least one dose of the CYFENDUS vaccine.
- The vaccine was given because you were exposed to anthrax during a large-scale exposure event.
- The exposure event happened in the United States.
- You may have also taken antibiotics as part of your treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at patients who have been diagnosed with or are suspected to have systemic anthrax and are being treated with the medicine AIGIV. It aims to understand how well the treatment works and whether it is safe. The results may help improve care for people with this serious infection.
This study is for people who have symptoms of inhalational anthrax after a mass exposure. It tests a medicine called raxibacumab to see if it helps and is safe. Anyone who receives this medicine as part of their care can join.
This study observes people in the US who have been diagnosed with systemic anthrax and treated with a medication called raxibacumab, which was given from a national emergency supply. The goal is to learn more about how this treatment works in real-world cases.
This study looks at whether taking a short course of antibiotics changes how well vaccines work. You would receive the BCG vaccine (for tuberculosis) and possibly the yellow fever vaccine, and we would check your immune response over several months.
This study tests whether a short course of a strong antibiotic (ceftriaxone) can help people who still have fatigue and other symptoms after being treated for Lyme disease. It aims to see if this treatment can improve your quality of life.
This study tests a single dose of a new medication called SYH2061 to see if it is safe and how the body processes it. It is for healthy adults aged 18 to 55 who have had certain vaccines and are willing to follow study rules.
Hear when a new Anthrax trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.